Ingemuva
Izindlela zokwelapha ezisekelwe ku-Incretin sekuyisikhathi eside zaziwa ngokuthuthukisa kokubiliukulawula ushukela wegazifuthiukunciphisa umzimba. Izidakamizwa zendabuko ze-incretin ngokuyinhloko zihloseI-GLP-1 receptor, ngenkathiI-Tirzepatideimele isizukulwane esisha “twincretin” ama-agent — asebenzakokubili i-GIP (i-insulinotropic polypeptide encike kuglucose)futhiI-GLP-1ama-receptors.
Lesi senzo esikabili sibonisiwe ukuthi sithuthukisa izinzuzo ze-metabolic futhi sikhuthaze ukuncipha okukhulu kwesisindo uma kuqhathaniswa nama-agonists e-GLP-1 kuphela.
I-SURMOUNT-1 Study Design
SURMOUNT-1kwaba aokungahleliwe, okungaboni kabili, ukuhlolwa komtholampilo kwesigaba sesi-3kwenziwa kuzo zonke izindawo eziyi-119 emazweni ayisishiyagalolunye.
Abahlanganyeli bahlanganisa abantu abadala ababe:
- Ukukhuluphala(BMI ≥30), noma
- Ukukhuluphala ngokweqile(BMI ≥ 27) okungenani okukodwa okuhambisana nesisindo (isb, umfutho wegazi ophezulu, i-dyslipidemia, i-apnea yokulala, noma isifo senhliziyo).
Abantu abanesifo sikashukela, ukusetshenziswa kwezidakamizwa zakamuva zokwehlisa isisindo, noma ukuhlinzwa kwangaphambili kwe-bariatric akufakiwe.
Abahlanganyeli babelwa ngokungahleliwe ukuthi bathole imijovo kanye ngeviki:
- Tirzepatide 5 mg, 10 mg, 15 mg, noma
- I-Placebo
Bonke ababambiqhaza nabo bathole isiqondiso sendlela yokuphila:
- A ukuntuleka kwekhalori ku-500 kcal / ngosuku
- OkungenaniImizuzu eyi-150 yokuzivivinya ngeviki
Ukwelashwa kwaqhubeka72 amasonto, kuhlanganise aIsigaba sokukhuphuka komthamo wamaviki angama-20kulandelwa isikhathi sokulungisa samasonto angama-52.
Uhlolojikelele lwemiphumela
Isamba se2,359 ababambiqhazababhaliswa.
Isilinganiso sobudala sasinjaloIminyaka engu-44.9, U-67.5% bekungabesifazane, ngenhliziyoisisindo somzimba 104.8 kgfuthiI-BMI engu-38.0.
Ukunciphisa Isisindo Somzimba Okusho ukuthini Evikini lama-72
| I-Dose Group | % Ukushintsha Kwesisindo | Ukushintsha Kwesisindo (kg) | Ukulahlekelwa Okungeziwe vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | - 16.1 kg | -13.5% |
| 10 mg | -19.5% | - 22.2 kg | -18.9% |
| 15 mg | -20.9% | - 23.6 kg | -20.1% |
| I-Placebo | -3.1% | - 2.4 kg | - |
I-Tirzepatide ithole u-15-21% okusho ukunciphisa isisindo somzimba, ebonisa imiphumela ecacile encike kumthamo.
Amaphesenti Ababambiqhaza Abazuza Ukuncipha Kwesisindo Okuqondisiwe
| Ukuncipha kwesisindo (%) | 5 mg | 10 mg | 15 mg | I-Placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Ngaphezu kwesigamuyabahlanganyeli abatholayo≥10 mgI-Tirzepatide ifinyelelwe≥20% ukwehla kwesisindo, isondela kumphumela obonwa ngokuhlinzwa kwe-bariatric.
Izinzuzo zeMetabolic nezenhliziyo
Uma kuqhathaniswa ne-placebo, i-Tirzepatide ithuthuke kakhulu:
- Isiyingi sokhalo
- I-Systolic blood pressure
- Iphrofayili ye-lipid
- Ukuzila ukudla kwe-insulin
Phakathi kwabahlanganyeli ngei-prediabetes, U-95.3% ubuyele kumazinga eglucose ajwayelekile, uma kuqhathaniswa61.9%eqenjini le-placebo - okubonisa ukuthi i-Tirzepatide ayisizi nje kuphela ekwehliseni isisindo kodwa futhi ithuthukisa i-glucose metabolism.
Ukuphepha Nokubekezeleleka
Imiphumela emibi kakhulu yayiyiyoemathunjini, kuhlanganiseisicanucanu, isifo sohudo, nokuqunjelwa, ngokuvamile imnene futhi iyadlula.
Izinga lokuyekisa ukuqhubeka ngenxa yezehlakalo ezingezinhle lalicishe libe4–7%.
Ukufa okumbalwa kwenzeka ngesikhathi sokuqulwa kwecala, okuxhunyaniswe kakhulu naloI-COVID-19, futhi bezingahlobene ngokuqondile nomuthi wocwaningo.
Akukho mehluko obalulekile obonwe ezinkingeni ezihlobene ne-gallbladder.
Ingxoxo
Ukuguqulwa kwendlela yokuphila kuphela (ukudla nokuzivocavoca) kuvame ukukhiqiza kuphela~ 3% ukuncipha kwesisindo esimaphakathi, njengoba kubonakala eqenjini le-placebo.
Ngokuphambene, i-Tirzepatide inikwe amandla15-21% isamba sokunciphisa isisindo somzimba, emele a5-7 izikhathi ezinkulu umphumela.
Uma kuqhathaniswa ne:
- Imithi yokwehlisa isisindo ngomlomo:ngokuvamile ukuzuza ukulahlekelwa okungu-5–10%.
- Ukuhlinzwa kwe-Bariatric:izuza > ukulahlekelwa okungu-20%.
I-Tirzepatide ivala igebe phakathi kokungenelela kwe-pharmacologic kanye nokuhlinzwa - ukunikelaenamandla, non-invasive isisindo ukunciphisa.
Okubaluleke kakhulu, ukukhathazeka mayelana nokuwohloka kwe-glucose metabolism akuzange kubonwe. Ngokuphambene nalokho, i-Tirzepatide ithuthukise ukuzwela kwe-insulin futhi yahlehlisa i-prediabetes kubahlanganyeli abaningi.
Kodwa-ke, lolu cwaningo lwaqhathanisa i-Tirzepatide ne-placebo - hhayi ngokuqondileI-Semaglutide.
Ukuqhathaniswa kwekhanda kuya kwekhanda kuyadingeka ukuze kunqunywe ukuthi iyiphi i-ejenti ekhiqiza ukulahlekelwa kwesisindo esikhulu.
Isiphetho
Kubantu abadala abanokukhuluphala ngokweqile noma ukukhuluphala ngokweqile kanye ne-comorbidities ehlobene, ukwengezakanye ngeviki Tirzepatideohlelweni lwendlela yokuphila ehlelekile (ukudla + ukuzivocavoca) kungaholela kulokhu:
- 15–21% isilinganiso sokunciphisa isisindo somzimba
- Ukuthuthukiswa okuphawulekayo kwe-metabolic
- Ukubekezelelana okuphezulu nokuphepha
Ngakho-ke i-Tirzepatide imele ukwelashwa okuphumelelayo nokuqinisekisiwe ngokomtholampilo kokulawulwa kwesisindo esimeme, okugadwa ngokwemithi.
Isikhathi sokuthumela: Oct-16-2025